# OnCo record third-arc-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/third-arc-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "third-arc-bio" ;
  schema:name "Third Arc Bio"@en ;
  schema:description "Third Arc Bio builds antibodies that link the immune system's T cells to cancer cells. Its first medicine, aimed at tumours carrying the protein Claudin 6, entered its first human trial in 2025."@en ;
  schema:url <https://onco.cc/companies/third-arc-bio/>, <https://www.thirdarcbio.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.thirdarcbio.com/>, <https://www.biospace.com/third-arc-bio-launches-with-oversubscribed-165-million-series-a-financing-to-deliver-superior-biologics-for-solid-tumors-and-inflammatory-immunology-i-i-diseases>, <https://www.thirdarcbio.com/news/third-arc-bio-announces-first-patient-dosed-in-phase-1-clinical-trial-of-lead-t-cell-engager-arc101-to-treat-cldn6-positive-cancers/>, <https://www.thirdarcbio.com/news/third-arc-bio-announces-$52m-series-a-extension-to-expand-oncology-and-immunology-&-inflammation-portfolio/> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/cldn6/>, <https://onco.cc/targets/cd3/> .